Fibrocell Science Inc (FCSC)

0.74
0.00 0.16
NASDAQ : Health Care
Prev Close 0.74
Open 0.74
Day Low/High 0.73 / 0.75
52 Wk Low/High 0.91 / 7.60
Volume 31.01K
Avg Volume 336.30K
Exchange NASDAQ
Shares Outstanding 43.90M
Market Cap 34.68M
EPS -0.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Fibrocell Announces Convertible Debt And Warrant Financing of Up To $25 Million

Fibrocell Announces Convertible Debt And Warrant Financing of Up To $25 Million

Terminates Previously Announced Underwritten Public Offering

Fibrocell Reports Second Quarter 2016 Financial Results And Recent Operational Highlights

Fibrocell Reports Second Quarter 2016 Financial Results And Recent Operational Highlights

Company to Host Conference Call and Webcast Today at 8:30 a.m. EDT

Fibrocell Science Stock Sees Short Interest Decrease By 24.4%

Fibrocell Science Stock Sees Short Interest Decrease By 24.4%

The most recent short interest data has been released for the 06/15/2016 settlement date, which shows a 845,388 share decrease in total short interest for Fibrocell Science, Inc. , to 2,622,567, a decrease of 24.38% since 05/31/2016.

These 5 Stocks Under $10 Are Set to Soar Higher

These 5 Stocks Under $10 Are Set to Soar Higher

Here's a technical look at how to trade several under-$10 stocks that are poised for breakouts.

Fibrocell Reports First Quarter 2016 Financial Results And Operational Highlights

Fibrocell Reports First Quarter 2016 Financial Results And Operational Highlights

Company to Host Conference Call and Webcast Today at 8:30 a.m. EDT

Fibrocell Receives Orphan Drug Designation From The FDA For FCX-013 For The Treatment Of Localized Scleroderma

Fibrocell Receives Orphan Drug Designation From The FDA For FCX-013 For The Treatment Of Localized Scleroderma

FCX-013 Gene-Therapy Product Candidate Offers Potential to Address Painful Fibrotic Disease

5 Stocks Under $10 Set to Soar

5 Stocks Under $10 Set to Soar

These under-$10 stock look poised to break out and trade higher from current levels.

Fibrocell Reports Fourth Quarter And Full Year 2015 Financial Results And Operational Highlights

Fibrocell Reports Fourth Quarter And Full Year 2015 Financial Results And Operational Highlights

Company to Host Conference Call and Webcast, Today at 8:30 a.m. EST

Fibrocell And Intrexon Announce Collaboration To Address Chronic Inflammatory And Degenerative Diseases Of The Joint

Fibrocell And Intrexon Announce Collaboration To Address Chronic Inflammatory And Degenerative Diseases Of The Joint

Companies to Develop Best-in-Class Treatment for Arthritis and Related Conditions Through Targeted, Long-term Therapeutic Delivery While Sparing Systemic Effects

FCSC: Insiders vs. Shorts

FCSC: Insiders vs. Shorts

The most recent short interest data was recently released by the NASDAQ for the 09/30/2015 settlement date, and Fibrocell Science, Inc. is one of the most shorted stocks of the Russell 3000, based on 8.20 "days to cover" versus the median component at 5.50.